CYDY Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors CytoDyn, Inc. Investigation and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CytoDyn, Inc. ("CytoDyn" or "the Company") (OTCQB:CYDY). Investors who purchased CytoDyn securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cydy.

The investigation concerns whether CytoDyn and certain of its officers and/or directors have violated federal securities laws.

On June 30, 2020, Citron Research published a report on CytoDyn alleging that the company is a "big joke" regarding its claim to have developed a cure for COVID-19 with "zero" data related to over-hyped leronlimab. Following this news, CytoDyn stock dropped during intraday trading on June 30, 2020.

If you are aware of any facts relating to this investigation or purchased CytoDyn shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cydy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 595820